HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -197.45 Million USD | 31.91% |
| 2022 | -289.97 Million USD | 15.58% |
| 2021 | -343.47 Million USD | -71.81% |
| 2020 | -199.92 Million USD | -126.99% |
| 2019 | -88.07 Million USD | -48.53% |
| 2018 | -59.29 Million USD | -7.27% |
| 2017 | -55.27 Million USD | -69.34% |
| 2016 | -32.64 Million USD | -280.76% |
| 2015 | 18.05 Million USD | 768.22% |
| 2014 | 2.08 Million USD | -55.22% |
| 2013 | 4.64 Million USD | 119.45% |
| 2012 | -23.88 Million USD | -0.67% |
| 2011 | -23.72 Million USD | -14.01% |
| 2010 | -20.8 Million USD | 37.87% |
| 2009 | -33.49 Million USD | -9.46% |
| 2008 | -30.6 Million USD | 34.59% |
| 2007 | -46.78 Million USD | -1483.25% |
| 2006 | -2.95 Million USD | -267.08% |
| 2005 | 1.76 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -118.25 Million USD | 40.11% |
| 2024 Q2 | -121.85 Million USD | 2.45% |
| 2023 Q2 | -182.84 Million USD | 0.0% |
| 2023 Q4 | -197.45 Million USD | 1.95% |
| 2023 Q3 | -201.38 Million USD | -10.14% |
| 2023 FY | -197.45 Million USD | 31.91% |
| 2023 Q1 | -182.84 Million USD | 36.94% |
| 2022 Q2 | -467.08 Million USD | 0.0% |
| 2022 Q3 | -289.97 Million USD | 37.92% |
| 2022 FY | -289.97 Million USD | 15.58% |
| 2022 Q4 | -289.97 Million USD | 0.0% |
| 2022 Q1 | -467.08 Million USD | -35.99% |
| 2021 Q2 | -550.74 Million USD | -78.37% |
| 2021 Q1 | -308.76 Million USD | -54.44% |
| 2021 Q3 | -343.47 Million USD | 37.63% |
| 2021 FY | -343.47 Million USD | -71.81% |
| 2021 Q4 | -343.47 Million USD | 0.0% |
| 2020 Q3 | -202.12 Million USD | -1073.17% |
| 2020 Q2 | -17.22 Million USD | -107.84% |
| 2020 FY | -199.92 Million USD | -126.99% |
| 2020 Q4 | -199.92 Million USD | 1.09% |
| 2020 Q1 | 219.7 Million USD | 343.18% |
| 2019 Q1 | -59.21 Million USD | -1.59% |
| 2019 FY | -88.07 Million USD | -48.53% |
| 2019 Q3 | -93 Million USD | -22.18% |
| 2019 Q2 | -76.11 Million USD | -28.55% |
| 2019 Q4 | -90.34 Million USD | 2.86% |
| 2018 FY | -59.29 Million USD | -7.27% |
| 2018 Q4 | -58.28 Million USD | 0.0% |
| 2018 Q2 | -48.63 Million USD | -113.57% |
| 2018 Q1 | 358.29 Million USD | 748.17% |
| 2017 FY | -55.27 Million USD | -69.34% |
| 2017 Q1 | -54.09 Million USD | -65.7% |
| 2017 Q4 | -55.27 Million USD | -4.9% |
| 2017 Q2 | -65.68 Million USD | -21.43% |
| 2017 Q3 | -52.69 Million USD | 19.77% |
| 2016 FY | -32.64 Million USD | -280.76% |
| 2016 Q1 | -19.01 Million USD | -205.27% |
| 2016 Q2 | -34.07 Million USD | -79.25% |
| 2016 Q3 | -22.27 Million USD | 34.63% |
| 2016 Q4 | -32.64 Million USD | -46.54% |
| 2015 Q3 | 15.03 Million USD | 730.43% |
| 2015 Q2 | 1.81 Million USD | -84.42% |
| 2015 Q4 | 18.05 Million USD | 20.08% |
| 2015 FY | 18.05 Million USD | 768.22% |
| 2015 Q1 | 11.62 Million USD | -18.47% |
| 2014 Q2 | -1.07 Million USD | -116.02% |
| 2014 FY | 2.08 Million USD | -55.22% |
| 2014 Q4 | 14.25 Million USD | 0.0% |
| 2014 Q1 | 6.69 Million USD | 44.16% |
| 2013 Q2 | 8.3 Million USD | 0.0% |
| 2013 FY | 4.64 Million USD | 119.45% |
| 2013 Q4 | 4.64 Million USD | -61.35% |
| 2013 Q3 | 12.01 Million USD | 44.7% |
| 2013 Q1 | 8.3 Million USD | 134.78% |
| 2012 Q2 | -25.57 Million USD | 0.0% |
| 2012 Q3 | -30.76 Million USD | -20.31% |
| 2012 FY | -23.88 Million USD | -0.67% |
| 2012 Q4 | -23.88 Million USD | 22.37% |
| 2011 FY | -23.72 Million USD | -14.01% |
| 2011 Q4 | -23.72 Million USD | 0.0% |
| 2010 Q4 | -20.8 Million USD | 0.0% |
| 2010 FY | -20.8 Million USD | 37.87% |
| 2010 Q2 | -23.67 Million USD | 0.0% |
| 2009 Q4 | -33.49 Million USD | 0.0% |
| 2009 FY | -33.49 Million USD | -9.46% |
| 2008 FY | -30.6 Million USD | 34.59% |
| 2007 FY | -46.78 Million USD | -1483.25% |
| 2006 FY | -2.95 Million USD | -267.08% |
| 2005 FY | 1.76 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 23.674% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 109.718% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 3421.972% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 165.484% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -937.178% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 738.032% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 9.931% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 177.083% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 152.3% |
| SSY Group Limited | 1.71 Billion HKD | 111.524% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -2568.712% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 158.516% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.387% |